459 related articles for article (PubMed ID: 27132279)
1. Role of the tumor microenvironment in mature B-cell lymphoid malignancies.
Fowler NH; Cheah CY; Gascoyne RD; Gribben J; Neelapu SS; Ghia P; Bollard C; Ansell S; Curran M; Wilson WH; O'Brien S; Grant C; Little R; Zenz T; Nastoupil LJ; Dunleavy K
Haematologica; 2016 May; 101(5):531-40. PubMed ID: 27132279
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.
Härzschel A; Zucchetto A; Gattei V; Hartmann TN
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210016
[TBL] [Abstract][Full Text] [Related]
4. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities.
Liu Y; Zhou X; Wang X
J Hematol Oncol; 2021 Aug; 14(1):125. PubMed ID: 34404434
[TBL] [Abstract][Full Text] [Related]
5. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.
Burger JA; Gribben JG
Semin Cancer Biol; 2014 Feb; 24():71-81. PubMed ID: 24018164
[TBL] [Abstract][Full Text] [Related]
6. Origin and pathogenesis of B cell lymphomas.
Seifert M; Scholtysik R; Küppers R
Methods Mol Biol; 2013; 971():1-25. PubMed ID: 23296955
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Mouse Models of B Cell Malignancies.
Perez-Chacon G; Vincent-Fabert C; Zapata JM
Front Immunol; 2021; 12():789901. PubMed ID: 34777400
[No Abstract] [Full Text] [Related]
8. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies.
Schultze JL; Gribben JG; Nadler LM
Curr Opin Oncol; 1998 Nov; 10(6):542-7. PubMed ID: 9818233
[TBL] [Abstract][Full Text] [Related]
10. The tumour microenvironment in B cell lymphomas.
Scott DW; Gascoyne RD
Nat Rev Cancer; 2014 Aug; 14(8):517-34. PubMed ID: 25008267
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.
Kedar R; Sabag O; Licthenstein M; Lorberboum-Galski H
Cancer; 2012 Dec; 118(24):6089-104. PubMed ID: 22692727
[TBL] [Abstract][Full Text] [Related]
12. Morphologic features of binucleated lymphocytes to assess the diagnosis of persistent B-cell polyclonal lymphocytosis or other mature B-cell neoplasms.
Lesesve JF; Gressot AL; Troussard X; Mossafa H; Cornet E
Leuk Lymphoma; 2014 Jul; 55(7):1551-6. PubMed ID: 24033110
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy.
Nicholas NS; Apollonio B; Ramsay AG
Biochim Biophys Acta; 2016 Mar; 1863(3):471-482. PubMed ID: 26554850
[TBL] [Abstract][Full Text] [Related]
14. Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers.
Andrews JM; Pyfrom SC; Schmidt JA; Koues OI; Kowalewski RA; Grams NR; Sun JJ; Berman LR; Duncavage EJ; Lee YS; Cashen AF; Oltz EM; Payton JE
EBioMedicine; 2021 Sep; 71():103559. PubMed ID: 34461601
[TBL] [Abstract][Full Text] [Related]
15. Microenvironment signaling driving lymphomagenesis.
Verdière L; Mourcin F; Tarte K
Curr Opin Hematol; 2018 Jul; 25(4):335-345. PubMed ID: 29746265
[TBL] [Abstract][Full Text] [Related]
16. cROSsing the Line: Between Beneficial and Harmful Effects of Reactive Oxygen Species in B-Cell Malignancies.
Domka K; Goral A; Firczuk M
Front Immunol; 2020; 11():1538. PubMed ID: 32793211
[TBL] [Abstract][Full Text] [Related]
17. Higher Incidence of B Cell Malignancies in Primary Immunodeficiencies: A Combination of Intrinsic Genomic Instability and Exocytosis Defects at the Immunological Synapse.
Mastio J; Saeed MB; Wurzer H; Krecke M; Westerberg LS; Thomas C
Front Immunol; 2020; 11():581119. PubMed ID: 33240268
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.
Huang J; Fairbrother W; Reed JC
Expert Rev Hematol; 2015 Jun; 8(3):283-97. PubMed ID: 25912824
[TBL] [Abstract][Full Text] [Related]
19. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
Yang L; Li A; Lei Q; Zhang Y
J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders.
Bao Y; Cao X
Clin Rev Allergy Immunol; 2016 Jun; 50(3):301-11. PubMed ID: 26066671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
